Ermias D. Belay

Ermias D. Belay

Auto-generated profile, based on publicly available information

Ermias D. Belay

Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Epidemiology
Verified
Journal Article
Open access
RURitei Uehara
Ritei Uehara
EBErmias D. Belay
Ermias D. Belay
Kawasaki disease (KD) is a systemic vasculitis that mainly affects children younger than 5 years. Although Dr. Tomisaku Kawasaki first reported KD over 40 years ago, the cause of the disease remains unknown. Currently, KD has been diagnosed in more than 60 countries, including those in Asia, the Middle East, Latin America, and Africa, as well as in North America and Europe. The purpose of this review is to describe the epidemiologic features of KD—particularly its incidence, seasonality, and the occurrence of coronary artery abnormalities—primarily in Japan and the United States, but also in Europe and other Asian countries.

1 June 2010 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
RHRobert C. Holman
Robert C. Holman
EBErmias D. Belay
Ermias D. Belay
KCKrista Y. Christensen
Krista Y. Christensen
AFArianne M. Folkema
Arianne M. Folkema
CSClaudia A. Steiner
Claudia A. Steiner
LSLawrence B. Schonberger
Lawrence B. Schonberger
The present study describes the rate and trends of childhood hospitalizations with Kawasaki syndrome (KS) in the United States. Retrospective analysis of hospitalizations with KS among children <18 years of age in the United States using the Kids' Inpatient Database (1997, 2000, 2003, and 2006) and the Nationwide Inpatient Sample (1998-2007). The KS-associated hospitalization rate for children <5 years of age was 20.8 (95% CI: 18.5-23.1) per 100,000 children in 2006. Annual rates remained constant during the study period, except for a peak in 2005. In 2006, 76.8% (SE = 0.9%) of an estimated 5523 (SE = 289) KS-associated hospitalizations among children <18 years of age were <5 years of age. The mean age for all children at hospitalization was 3.0 years (SE <0.1); 25.7 months (SE = 0.3) for children <5 years of age, and 24.8 months (SE = 0.4) and 27.1 months (SE = 0.5) for boys and girls, respectively. The rate for boys was higher than that for girls (24.2 [95% CI: 21.3-27.1] and 16.8 [95% CI: 14.7-18.9], respectively). The rate for Asian/Pacific Islander children (30.3 [95% CI: 20.2-40.4]) was the highest among the racial groups. The national KS-associated annual hospitalization rate for children <5 years of age from 1997 to 2007 was relatively stable and was similar to previously published rates, except for an increase in 2005. Most hospitalizations were in children <3 years of age with few hospitalizations during the first 2 months of age. Children of Asian/Pacific Islander descent had the highest hospitalization rate.

6 May 1999 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
EBErmias D. Belay
Ermias D. Belay
JBJoseph S. Bresee
Joseph S. Bresee
RHRobert C. Holman
Robert C. Holman
AKAli S. Khan
Ali S. Khan
ASAbtin Shahriari
Abtin Shahriari
LSLawrence B. Schonberger
Lawrence B. Schonberger
Reye's syndrome is characterized by encephalopathy and fatty degeneration of the liver, usually after influenza or varicella. Beginning in 1980, warnings were issued about the use of salicylates in children with those viral infections because of the risk of Reye's syndrome.

20 June 2008 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
PGPierluigi Gambetti
Pierluigi Gambetti
ZDZhiqian Dong
Zhiqian Dong
JYJue Yuan
Jue Yuan
XXXiangzhu Xiao
Xiangzhu Xiao
MZMengjie Zheng
Mengjie Zheng
WZWen-Quan Zou
Wen-Quan Zou
Objective: To report a novel prion disease characterized by distinct histopathological and immunostaining features, and associated with an abnormal isoform of the prion protein (PrP) that, contrary to the common prion diseases, is predominantly sensitive to protease digestion.Methods: Eleven subjects were investigated at the National Prion Disease Pathology Surveillance Center for clinical, histopathological, immunohistochemical, genotypical, and PrP characteristics.Results: Patients presented with behavioral and psychiatric manifestations on average at 62 years, whereas mean disease duration was 20 months. The type of spongiform degeneration, the PrP immunostaining pattern, and the presence of microplaques distinguished these cases from those with known prion diseases. Typical protease‐resistant PrP was undetectable in the cerebral neocortex with standard diagnostic procedures. After enrichment, abnormal PrP was detected at concentrations 16 times lower than common prion diseases; it included nearly 4 times less protease‐resistant PrP, which formed a distinct electrophoretic profile. The subjects examined comprised about 3% of sporadic cases evaluated by the National Prion Disease Pathology Surveillance Center. Although several subjects had family histories of dementia, no mutations were found in the PrP gene open reading frame.Interpretation: The distinct histopathological, PrP immunohistochemical, and physicochemical features, together with the homogeneous genotype, indicate that this is a previously unidentified type of disease involving the PrP, which we designated “protease‐sensitive prionopathy” (or PSPr). Protease‐sensitive prionopathy is not rare among prion diseases, and it may be even more prevalent than our data indicate because protease‐sensitive prionopathy cases are likely also to be classified within the group of non‐Alzheimer's dementias. Ann Neurol 2008;63:697–708

1 August 2021 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
EBErmias D. Belay
Ermias D. Belay
JAJoseph Abrams
Joseph Abrams
MOMatthew E. Oster
Matthew E. Oster
JGJennifer Giovanni
Jennifer Giovanni
TPTimmy Pierce
Timmy Pierce
SGShana Godfred-Cato
Shana Godfred-Cato
Patients with manifestations compatible with multisystem inflammatory syndrome in children (MIS-C) were first identified in April 2020 during the height of the COVID-19 pandemic in the United Kingdom.1 Patients had hyperinflammatory shock with features similar to Kawasaki disease and toxic shock syndrome. The report alerted clinicians and public health authorities worldwide, and similar patients were subsequently identified in Europe, the United States, and other countries.2-7 Most patients with MIS-C presented with fever, signs of generalized inflammation, hypotension and shock, and multiple organ dysfunction.7,8

2 August 2010 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
WZWen-Quan Zou
Wen-Quan Zou
GPGianfranco Puoti
Gianfranco Puoti
XXXiangzhu Xiao
Xiangzhu Xiao
JYJue Yuan
Jue Yuan
LQLiuting Qing
Liuting Qing
PGPierluigi Gambetti
Pierluigi Gambetti